Document is current
Any future updates will be listed below
-
Authors
George, Jasmine
Ma, Xiaolong https://orcid.org/0009-0009-9196-182X
Kadamberi, Ishaque Pulikkal
Nair, Ajay
Mittal, Sonam
Hashemi, Elaheh
Kumar, Sudhir
Singh, Mona
Geethadevi, Anjali
Pradeep, Meenakshi
Nair, Anupama
Tsaih, Shirng-Wern https://orcid.org/0000-0002-9836-4659
Jorns, Julie M.
Malarkannan, Subramaniam
Dietlein, Felix https://orcid.org/0000-0002-6651-7155
Lin, Chien-Wei https://orcid.org/0000-0003-4023-7339
Pradeep, Sunila https://orcid.org/0000-0003-2441-7727
Chaluvally-Raghavan, Pradeep https://orcid.org/0000-0002-8268-3460
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI R01CA229907)
- License Information
-
More Information
Article History
Received: 15 January 2025
Accepted: 20 March 2026
First Online: 3 April 2026
Competing interests
: P.C.-R, S.P., and J.G. are inventors of a US provisional patent application 63/683,329 entitled compositions targeting FXR1 and methods of using the same for the treatment of diseases and disorders associated with FXR1 expression. The remaining authors declare no competing interests.
